Mounjaro (tirzepatide) / Eli Lilly - LARVOL DELTA

The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity. (PubMed, Nutrition) - "While underweight status and malnutrition are important underpinnings of functional hypothalamic amenorrhea, the rising prevalence of overweight and obesity poses a growing risk to menstrual health in adolescents. Early, comprehensive, and personalized strategies that integrate nutrition, physical activity, psychological support, and, when appropriate, insulin sensitizers and other pharmacotherapies can help protect and enhance reproductive endocrine function, preserve fertility, and mitigate long-term health risks. Further research is needed to clarify the impact and long-term effects of novel weight-loss medications in order to inform clinical practice in adolescent care."

Journal • Review • Genetic Disorders • Inflammation • Obesity • Polycystic Ovary Syndrome • Women's Health • LEP

SURPASS-CVOT: Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=70000 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | N=50000 ➔ 70000 | Trial completion date: Jun 2025 ➔ Mar 2026 | Trial primary completion date: Jan 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar (ASH 2025) - "A search of FAERS captured 54 other users of semaglutide, liraglutide, and tirzepatide with (immune) thrombocytopenia...TriNetX Global Collaborative Database Review showed that among both patients with diabetes and patients with obesity but without diabetes, semaglutide use was associated with a lower risk of thrombocytopenia compared with older diabetes and weight loss medications... The SONAR-AI approach facilitated the first comprehensive description of four cases of GLP-1 receptor agonist-associated thrombocytopenia. This effort was completed in four weeks and cost $500. The four cases have been the first comprehensively described cases submitted to FAERS."

Clinical • Diabetes • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Metabolic Disorders • Obesity • Thrombocytopenia • Thrombocytopenic Purpura

Obesity as a chronic disease: the key role of new therapies (PubMed, Assist Inferm Ric) - "The introduction of GLP-1 receptor agonists-such as liraglutide and semaglutide-has transformed obesity management by producing substantial weight reduction and improving risks of diabetes, cardiovascular disease, and sleep apnea...Concerns also include reductions in lean mass, high treatment costs, and misuse driven by social media. Ensuring appropriate use requires medical supervision, preventive strategies, and public awareness efforts."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

The committee recommended a change to extend the use of Mounjaro (tirzepatide) for the treatment of type 2 diabetes, that is not satisfactorily controlled, to adolescents and children from 10 years of age, together with diet and physical activity. (European Medicines Agency)

CHMP • Type 2 Diabetes Mellitus

GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review. (PubMed, Ann Med Surg (Lond)) - "Semaglutide (~7 days) and tirzepatide (~5 days) have long half-lives, requiring discontinuation at least 35 days and 25-35 days, respectively, before conception, while liraglutide requires ≥3 days...Alternatives such as metformin, lifestyle modification, and bariatric surgery remain safer options...Preconception discontinuation timed to each agent's half-life is prudent to minimize potential fetal exposure. Prospective studies and pregnancy registries are needed to confirm reproductive safety and refine guidance."

Journal • Review • Diabetes • Genetic Disorders • Infertility • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome • Sexual Disorders • Type 2 Diabetes Mellitus

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. (PubMed, J Clin Med) - "(5) The mineralocorticoid receptor antagonist (MRA) finerenone has been tested in RCTs as a kidney protective agent...Many novel agents-many of them proven not only for DM management but also for the treatment of obesity with or without DM or heart failure (HF)-are now in development and may be added to the five classical pillars: other non-steroidal MRA (balcinrenone); aldosterone synthase inhibitors (baxdrostat and vicadrostat); other GLP-1 RA (tirzepatide, survodutide, retatrutide, and cagrilintide); ET1 R antagonists, (zibotentan); and soluble guanylate cyclase activators (avenciguat). These new agents aim to slow disease progression further and reduce cardiovascular risk. Future strategies rely on integrated, patient-centered approaches and personalized therapy to curb renal disease and its related complications."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease

Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH). (PubMed, Diabetes Obes Metab) - "Clinically available medications are beneficial in reversing MASH. Improvements in RSw/oF and RFw/oS were greater at earlier stages of fibrosis. Future analyses of drug effects should include assessments adjusted for baseline study characteristics of Fibrosis Grades and may evaluate whether preventive therapy will have long term benefits if started at earlier stages of MASLD."

Journal • Retrospective data • Fibrosis • Hepatitis C • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study. (PubMed, J Pediatr Endocrinol Metab) - "This first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 1 Diabetes Mellitus

Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review. (PubMed, Cureus) - "Its therapeutic potential was long realized, leading to the development of the first GLP-1 receptor agonist, exenatide, followed by liraglutide, dulaglutide, semaglutide, and tirzepatide...Alongside resmetirom, semaglutide is currently approved for the treatment of non-cirrhotic MASH with moderate-to-advanced fibrosis. Safety considerations include gastrointestinal intolerance, hypoglycemia, rare pancreaticobiliary events, and theoretical concerns of thyroid C-cell tumors, though human risk remains minimal. In summary, semaglutide extends the armamentarium of the hepatologist against the most common liver disease worldwide."

Journal • Review • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Hypoglycemia • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis. (PubMed, BMJ Open) - "Semaglutide, tirzepatide and liraglutide are approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of type 2 diabetes mellitus and overweight...Findings of this systematic review will be published in international peer-reviewed scientific journals. CRD42024623312."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

SynergyRx is a telemedicine platform offering online GLP-1 prescriptions including semaglutide and tirzepatide for eligible adults seeking medically supervised weight management. (Newswire) - "The service provides virtual consultations with licensed healthcare providers, home medication delivery, 24/7 patient support with provider access included, and transparent self-pay pricing with current promotional packages starting at $200 plus free expedited shipping as of November 2025. The platform currently operates across all 50 U.S. states, subject to state telehealth and prescribing regulations, and reports serving more than 50,000 patients as of late 2025."

Commercial • Obesity

Regulator releases new safety warnings for weight loss and diabetes drugs including Ozempic, Wegovy and Mounjaro (News.com.au) - "The safety alert issued by the regulator on Monday details links to two separate safety issues; the potential risk of suicidal thoughts, and reduced effectiveness of oral contraception...It relates to GLP-1 and dual GIP/GLP-1 receptor agonists which are primarily prescribed to manage type 2 diabetes and obesity, and are marketed in Australia as Ozempic (semaglutide) Wegovy (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Mounjaro (tirzepatide)."

Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

WHO backs GLP-1 treatments to tackle obesity epidemic (CTV News) - "A new generation of appetite-suppressing drugs called GLP-1 agonists -- which includes blockbuster brands Ozempic and Mounjaro -- has become massively popular in recent years. On Monday, the United Nations health agency issued its first guidelines on how such drugs could be used as a key tool for treating obesity in adults as a chronic, relapsing disease....The new guidelines are calling for GLP-1 therapies to be used by adults, excluding pregnant women, ]for the long-term treatment of obesity'. WHO highlighted that while the efficacy of the therapies in treating obesity was 'evident', more data was needed on efficacy and safety over longer periods."

Clinical guideline • Obesity

Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders. (PubMed, Clin Mol Hepatol) - "Tirzepatide (GLP-1/GIP dual agonist), CagriSema (GLP-1/amylin dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist) have achieved unprecedented levels of weight loss and glycemic improvement, with certain agents also demonstrating hepatic, cardiovascular, and inflammatory benefits. Non-peptidyl oral GLP-1RAs, such as orforglipron, offer novel formulation strategies to enhance treatment accessibility and adherence...These therapies are poised to emerge as key components of precision metabolic medicine. This review article explores the mechanistic basis, pharmacological characteristics, and clinical data supporting the use of engineered NUSH-based peptide therapies for obesity and its related metabolic disorders, with particular emphasis on recent progress in the development and clinical application of dual and triple agonists."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. (PubMed, J Obes) - "Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label...Novel agents including CagriSema and higher dose oral semaglutide are advancing through clinical trials, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape...The convergence of pharmacological innovation, digital health strategies, and equitable care initiatives is expected to revolutionize obesity therapeutics in the coming decade. Priorities for future research include sustaining long-term weight loss, establishing disease-modifying potential in nonmetabolic disorders, and addressing health equity concerns to ensure broader global benefit."

Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison (Cureus) - "A total of 100 participants (58 tirzepatide, 42 semaglutide; median age 27 years) were included, with 87 (87%) being female. Baseline BMI was higher in the tirzepatide group (36.6±4.77 vs. 32.3±3.55 kg/m²; p<0.001). Both drugs produced significant weight loss, with tirzepatide achieving greater reductions than semaglutide (8.53±4.10 vs. 6.85±3.38 kg; p=0.033). Clinically meaningful weight loss (≥5%) was observed in 89 (89%) of participants, and ≥10% loss in 33 (33%), with higher proportions in the tirzepatide group."

Retrospective data • Obesity

As next-generation anti-obesity drugs are being developed one after another, the obesity drug market is expected to be reshaped next year, centering on so-called "oral Mounjaro" and "high-dose Wegovy." (The Asia Business Daily)

Launch non-US • Obesity

Cipla has announced the launch of Yurpeak (tirzepatide), a once-a-week injectable treatment designed to help manage both obesity and type 2 diabetes — two health issues that are growing rapidly in India. (Business Upturn) - "Yurpeak will be available only on prescription and will come in the easy-to-use KwikPen device. Patients will have access to six dosing strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — giving doctors flexibility to tailor the treatment as needed."

Launch non-US • Obesity • Type 2 Diabetes Mellitus

Mounjaro linked to 35 adverse event reports in Korea after launch (Chosun Biz) - "...Data submitted by the Korea Institute of Drug Satety & Risk Management under the Ministery of Food and Drug Safety showing that 35 adverse events were reported through Sept. Two serious adverse events, including diarrhea and hypoglycemic shock, were also included....However, adverse drug reactions reported to the Korea Institute of Drug Satety & Risk Management include cases where a causal relationship with the drug has not been established."

Adverse events • Obesity

Tirzepatide is Associated with Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients with Type 2 Diabetes. (PubMed, Am J Ophthalmol) - "Tirzepatide use was associated with a significantly reduced risk of developing POAG, OHTN, and need for first-line glaucoma treatment compared to selective GLP-1 RAs in patients with T2DM. These findings suggest a potential additional ocular benefit of tirzepatide and support further investigation into its role in glaucoma management."

Journal • Cardiovascular • Diabetes • Glaucoma • Metabolic Disorders • Ophthalmology • Type 2 Diabetes Mellitus

Mounjaro trial begins in Manchester (BBC) - "The first batch of patients visited a GP to be enrolled in the study that will assess the health benefits of anti-obesity drug Tirzepatide, sold under the brand name Mounjaro."

Trial status • Obesity

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. (PubMed, Ann Intern Med) - "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for type 2 diabetes mellitus (T2DM) and overweight or obesity, but their association with cancer is unclear...None. (PROSPERO: CRD42024608365)."

Journal • Retrospective data • Review • Brain Cancer • Breast Cancer • Diabetes • Endometrial Cancer • Gastric Cancer • Genetic Disorders • Hematological Malignancies • Kidney Cancer • Meningioma • Metabolic Disorders • Multiple Myeloma • Obesity • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm. (PubMed, Rev Cardiovasc Med) - "Instead, an integrated, patient-centered approach, with early screening and multidisciplinary management, is needed to address this complex interplay. Moreover, recognizing the shared pathways of T2D, MASLD, and CVD may help clinicians anticipate potential complications and design more effective and sustainable strategies for long-term outcomes."

Journal • Review • Cardiovascular • Diabetes • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge. (PubMed, J Diabetes Metab Disord) - "Notably, the inclusion of glucagon-like peptide-1 (GLP-1) receptor agonists-semaglutide, liraglutide, dulaglutide-and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, represents a paradigm shift in the management of type 2 diabetes mellitus (T2DM) and obesity...However, challenges persist, including financial constraints, limited healthcare infrastructure, and risks of irrational use, particularly for obesity alone. Effective implementation through national policies, training, and rational prescribing frameworks is essential to translating this global milestone into tangible public health benefits and to reducing the growing burden of diabetes and obesity worldwide."

Journal • Cardiovascular • Chronic Kidney Disease • Cystic Fibrosis • Dermatology • Diabetes • Genetic Disorders • Hematological Disorders • Hemophilia • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Oncology • Psoriasis • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus